Gamma-Carboline Therapy for PTSD Agitation and Impulse Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for posttraumatic stress disorder (PTSD) and impulse control disorder (ICD), such as intermittent explosive disorder (IED), are inadequate, with limited efficacy and low remission rates, particularly for severe chronic cases, and there is a need for new therapeutic agents that can effectively manage agitation, aggressive behaviors, and poor impulse control.
Innovation Solution
The use of specific substituted heterocycle fused gamma-carbolines, either alone or in combination with antidepressants like SSRIs, to treat PTSD and ICD, targeting 5-HT2 receptors and normalizing brain dopamine activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antidepressant therapies are used to treat PTSD and ICD, then treatment is provided, but efficacy is limited and remission rates are low
Solution Approach 1:
The patent introduces a novel chemical compound with a specific molecular structure (substituted heterocycle fused gamma-carboline) that interacts with serotonin receptors differently than existing antidepressants. This structural parameter change enables new pharmacological activity with improved efficacy for PTSD and impulse control disorders, achieving higher remission rates in severe and chronic cases where traditional therapies fail
2Reliability
If new treatment compounds are developed to improve efficacy, then treatment effectiveness increases, but treatment complexity and development requirements increase
Solution Approach 1:
The patent isolates and develops a specific active pharmacophore (the substituted heterocycle fused gamma-carboline structure) that can be administered as a discrete compound. This extraction of the key therapeutic element allows for standardized dosing and administration without requiring complex combination therapies, maintaining treatment simplicity while achieving improved remission rates
Data Source
AI summary
Use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of agitation, aggressive behaviors, posttraumatic stress disorder or impulse control disorders.